2. Academic Validation
  3. Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses

Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses

  • J Nat Prod. 2022 Oct 12;acs.jnatprod.2c00550. doi: 10.1021/acs.jnatprod.2c00550.
Shun Saito 1,  Kayo Funayama 1,  Wataru Kato 1,  Mayu Okuda 1,  Meiko Kawamoto 1,  Teruhiko Matsubara 1,  Toshinori Sato 1,  Akihiko Sato 2 3,  Satoko Otsuguro 4,  Michihito Sasaki 3,  Yasuko Orba 3 5,  Hirofumi Sawa 3 5 6 7,  Katsumi Maenaka 4,  Kazutoshi Shindo 8,  Masaya Imoto 9,  Midori A Arai 1
Affiliations

Affiliations

  • 1 Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama223-8522, Japan.
  • 2 Drug Discovery and Disease Research Laboratory, Shionogi & Co., Ltd., Osaka541-0045, Japan.
  • 3 Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo001-0020, Japan.
  • 4 Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo060-0812, Japan.
  • 5 International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo001-0020, Japan.
  • 6 One Health Research Center, Hokkaido University, Sapporo060-0818, Japan.
  • 7 Global Virus Network, Baltimore, Maryland21201, United States.
  • 8 Department of Food and Nutrition, Japan Women's University, Tokyo112-8681, Japan.
  • 9 Department of Neurology, Juntendo University School of Medicine, Tokyo113-8431, Japan.
PMID: 36223390 DOI: 10.1021/acs.jnatprod.2c00550
Abstract

Dihydromaniwamycin E (1), a new maniwamycin derivative featuring an azoxy moiety, has been isolated from the culture extract of thermotolerant Streptomyces sp. JA74 along with the known analogue maniwamycin E (2). Compound 1 is produced only by cultivation of strain JA74 at 45 °C, and this type of compound has been previously designated a "heat shock metabolite (HSM)" by our research group. Compound 2 is detected as a production-enhanced metabolite at high temperature. Structures of 1 and 2 are elucidated by NMR and MS spectroscopic analyses. The absolute structure of 1 is determined after the total synthesis of four stereoisomers. Though the absolute structure of 2 has been proposed to be the same as the structure of maniwamycin D, the NMR and the optical rotation value of 2 are in agreement with those of maniwamycin E. Therefore, this study proposes a structural revision of maniwamycins D and E. Compounds 1 and 2 show inhibitory activity against the influenza (H1N1) virus Infection of MDCK cells, demonstrating IC50 values of 25.7 and 63.2 μM, respectively. Notably, 1 and 2 display Antiviral activity against SARS-CoV-2, the causative agent of COVID-19, when used to infect 293TA and VeroE6T cells, with 1 and 2 showing IC50 values (for Infection of 293TA cells) of 19.7 and 9.7 μM, respectively. The two compounds do not exhibit cytotoxicity in these cell lines at those IC50 concentrations.

Figures
Products